Drug intelligence / Profile preview

PB-301

Development stage: Unknown
Lead developer: PB Immune Therapeutics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

PB-301 is an investigational exosome-based therapeutic under development by PB Immune Therapeutics. It is being explored for the treatment of neoplasms (cancers). The drug is currently in the discovery phase, and detailed information about its mechanism of action, specific molecular targets, or additional indications has not been disclosed publicly. Exosome therapies typically leverage naturally occurring extracellular vesicles to deliver therapeutic payloads to target cells, but further specifics for PB-301 have not been provided[1][4].

Other names: PB 301PB301PB-301

Beyond the preview

Go deeper on PB-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB-301.

Explore the full profile